恩度联合NP或GP方案一线治疗晚期非小细胞肺癌疗效比较

Endostar combined with NP or GP as first-line treatment options in advanced non-small cell lung cancer

目的研究恩度联合不同标准含铂化疗方案一线治疗晚期非小细胞肺癌的疗效差异。方法晚期非小细胞肺癌患者分别接受恩度联合标准NP/NC(长春瑞滨+顺铂/卡铂)或GP/GC(吉西他滨+顺铂/卡铂)方案化疗,恩度于化疗周期第1～14 d使用,每天15mg。观察两组患者的客观缓解率、无进展生存期、总生存期等疗效指标有无差异。结果共有35例患者参与了该项临床研究,NP/NC组14例,GP/GC组21例。两组患者的客观缓解率分别为21.4%和14.3%(P=0.664),疾病控制率为78.6%和90.5%(P=0.369);中位无进展生存期分别为13.3个月和12.4个月(P=0.720),中位总生存期分别为21.8个月和24.4个月(P=0.811),各项临床疗效评价指标的差异均无统计学意义。亚组分析显示不同病理亚型、性别、年龄的亚组近期疗效及生存期也均无显著差异。结论恩度联合标准含铂方案一线治疗晚期NSCLC疗效和生存相似,对化疗方案似乎没有选择性。

Objective To observe the efficacy of endostatin injection（endostar） combined with NP（Vinorelbine puls cisplatin/ Carboplatin） or GP（gemcitabine plus cisplatin/Carboplatin） regimens as The first-line treatment options in patients with advanced non-small cell lung cancer（NSCLC）.Methods Patients with advanced NSCLC admitted with NP or GP respectively,and the same time two groups received endostar 15mg/day from dayl to 14.Comparing the response rate（RR）、progression-free survival（PFS） and overall survival（OS） of the two groups.Results There were 35 patients in other two groups,group of NP/NC 14 cases,group of GP/GC 21 cases.The RR were 21.4% and 14.3% respectively in two group,No significant difference（P=0.664）.Disease control rate（DCR） were 78.6% and 90.5%（P=0.369）.Median progression-free survival（MPFS） were 13.3 months and 12.4 months（P=0.720）.Median overall survival（MOS） were 21.8 months and 24.4 months（P=0.811）.No significant difference in two groups.In a subgroup analysis,there is no significant difference of the recent efficacy and OS between histologic subtype、sex and years in two groups.Conclusions Endostar combined with a platinum-based regimen as the first-line treatment options in patients with advanced NSCLC,there is no significant difference of the recent efficacy and OS between different regimen.